The trial is being conducted through researchers from the Kaiser Permanent Health Research Center in Portland, Oregon; The Department of Research and Evaluation in Pasadena, California; and the Research Division in Oakland, California.
“Kaiser Permanente is incredibly well positioned to respond to this public fitness emergency,” said Nicola Klein, MD, PhD, director of Kaiser Permanente’s Center for Vaccine Studies and lead researcher in the Northern California trial. “We have been a leader in vaccine studies for over 30 years and have participated in clinical trials for almost all licensed vaccines in the United States. We know that we can make a significant contribution to help determine whether this vaccine is effective in preventing COVID-19 disease. “
“Our researchers and physicians are eager to make a contribution to independent science that will ultimately lead to the progression of a vaccine opposite COVID-19,” said Stephen Fortmann, MD, Senior Scientific Director and Lead Researcher at the Kaiser Permanente Health Research Center. “We are working in partnership with researchers around the world to ensure that rapid and effective vaccines can be developed to save disease and save lives.
“This virus is a massive fitness risk and has profoundly affected the world, both economically and socially,” said William J. Towner, MD, Regional Medical Director of the Clinical Trials Research Division and lead researcher in the trial at Kaiser Permanente’s Research Department. Evaluation. “It is imperative that we locate an effective vaccine as soon as possible.”
Kaiser Permanente clinical trial participants must be members of the fitness plan for adults ages 18 to 85 who are not pregnant or who are not making plans to become pregnant during the trial.
The phase 3 trial is a randomized trial in which one part of the participants will get the vaccine and the other party will get a placebo. Neither participants nor doctors will know who is getting the placebo vaccine (known as a double-blind study). During this phase of the trial, knowledge on safety, immune reaction and efficacy will be collected as required through regulatory review.
Kaiser Permanente also plays a key role in the progression of some other COVID-19 experimental vaccine, jointly developed through the National Institute of Allergy and Infectious and Modern Diseases, Inc. The Kaiser Permanente Washington Health Research Institute in Seattle was the first site to enroll participants in the Phase 1 trial. The vaccine began phase 3 trials at the end of July.
Learn more about Kaiser Permanente’s role in studies, add studies on the progression of remedies and vaccines, or receive more information about this clinical trial.
About Kaiser Permanente
For 75 years, Kaiser Permanente has been committed to shaping the future of health and health care — and helping our members, patients, and communities experience more healthy years. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Since July 21, 1945, Kaiser Permanente’s mission has been to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.4 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education, and the support of community health. http://about.kp.org
For information, contact: [email protected], [email protected], 310-710-0321
Check the content to download the media: http://www.prnewswire.com/news-releases/kaiser-permanente-joins-late-stage-covid-19-vaccine-study-301111164.html
KAISER Permanente SOURCE